Burton G. Malkiel's most recent trade in Theravance Biopharma Inc was a trade of 22,044 Share Option (Right to Buy) done . Disclosure was reported to the exchange on May 2, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | Burton G. Malkiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 22,044 | 22,044 | - | - | Share Option (Right to Buy) | |
Theravance Biopharma Inc | Burton G. Malkiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 9,132 | 100,589 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Burton G. Malkiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 28,000 | 28,000 | - | - | Share Option (Right to Buy) | |
Theravance Biopharma Inc | Burton G. Malkiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 9,852 | 91,457 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Burton G. Malkiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 9,828 | 81,605 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Burton G. Malkiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 6,000 | 6,000 | - | - | Share Option (Right to Buy) |